Trajectories of laboratory findings and medication use for the cinacalcet users before and after cinacalcet initiation.

<p>Trajectories of laboratory findings and medication use for the cinacalcet users before and after cinacalcet initiation.</p

Cinacalcet initiation during the follow-up period, and mean hemoglobin level by time-varying cinacalcet status (user or non-user).

<p>Cinacalcet initiation during the follow-up period, and mean hemoglobin level by time-varying cinacalcet status (user or non-user).</p

Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on the odds of achieving the treatment target (intention-to-treat effect).

<p>Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on the odds of achieving the treatment target (intention-to-treat effect).</p

Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on hemoglobin levels (intention-to-treat effect).

<p>Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on hemoglobin levels (intention-to-treat effect).</p

Characteristics of the cinacalcet non-users at registry enrollment and of the cinacalcet initiators at the visit immediately prior to cinacalcet initiation.

<p>Characteristics of the cinacalcet non-users at registry enrollment and of the cinacalcet initiators at the visit immediately prior to cinacalcet initiation.</p

Cumulative proportion of the incidence of hospitalization owing to fractures.

<p>ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker.</p

Baseline characteristics of the participants.

<p>For continuous variables, median and interquartile ranges (IQR) are shown.</p><p>ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker</p><p>Baseline characteristics of the participants.</p

Crude, case-mix-adjusted, and multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use.

<p>The covariates included in each analytical model for adjustment were as follows: case-mix, age, sex, duration of dialysis, and causes of end-stage kidney disease. In the multivariate-adjusted model, in addition to those in the case-mix model, the following covariates were adjusted; body mass index; Kt/V; comorbidity of cardiovascular disease and/or diabetes mellitus; smoking; history of parathyroidectomy; prescriptions of anti-coagulants, vitamin D receptor activators, and phosphate binders; and serum levels of albumin, calcium, phosphorus, intact parathyroid hormone, alkaline phosphatase, and blood hemoglobin, in addition to systolic and diastolic blood pressure and the use of antihypertensive drugs (β-blockers, calcium channel blockers, diuretics, and others). HR: hazard ratio, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker.</p

Cumulative proportion of the incidence of hospitalization owing to fractures.

<p>ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker.</p

Multivariate-adjusted hazard ratios of hospitalization owing to fractures associated with angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use considering patients with different levels of parathyroid hormone, sex, or systolic blood pressure.

<p>The hazard ratio was obtained from the Cox regression model adjusted for the distribution of age; sex; duration of dialysis; causes of end-stage kidney disease; body mass index; Kt/V; comorbidity of cardiovascular disease or diabetes mellitus; smoking; history of parathyroidectomy; prescriptions of anti-coagulants, vitamin D receptor activators, and phosphate binders; and serum levels of albumin, calcium, phosphorus, parathyroid hormone, alkaline phosphatase, and blood hemoglobin, in addition to systolic and diastolic blood pressure and the use of antihypertensive drugs (β-blockers, calcium channel blockers, diuretics, and others). P values for interactions were obtained from the likelihood ratio test. CI: confidence interval, HR: hazard ratio, iPTH: intact parathyroid hormone, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker.</p